Status:
COMPLETED
Efficacy and Safety of Two Anti-T-lymphocyte Immune Globulin (ATG-F) Induction Regimens in Anew Kidney Transplant Patients
Lead Sponsor:
Astellas Pharma Inc
Conditions:
De Novo Kidney Transplant Patients
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
To investigate the efficacy and safety of ATG-F induction regimen using a single dose of ATG-F compared with a five-day dose regimen of ATG-F in anew kidney transplant recipients.
Detailed Description
To investigate the efficacy and safety of ATG-F induction regimen using a single dose of ATG-F compared with a five-day dose regimen of ATG-F in de novo kidney transplant recipients. The primary analy...
Eligibility Criteria
Inclusion
- Patient with end stage kidney disease who is a suitable candidate for primary kidney transplantation.
- Patients scheduled to undergo renal allograft transplantation with compatible ABO blood type.
- Peak PRA \<50%
- Females of childbearing potential must have a negative pregnancy test within 48hrs prior to randomization and reliable methods of contraception should be started 4 weeks prior to and during the whole study.
- Patients capable to understand the purposes and risks of the study, who are willing and able to participate in the study and from whom written and dated informed consent to participate in the study is obtained.
Exclusion
- Subject has previously received or is receiving an organ transplant other than kidney
- Subject is receiving double-kidney transplant.
- Subject is receiving an ABO incompatible or T-cells cross match positive transplant.
- Cold ischemia time of allograft is \> 24 hours before kidney transplantation surgery.
- Subject is receiving organ from a Human Leukocyte Antibody (HLA) identical donor.
- Known contraindication to administration of ATG-F, including:
- Subject has known hypersensitivity to rabbit proteins
- Subject with severe thrombocytopenia
- Subject with bacterial, viral or mycotic infections which are not under therapeutically control
- Subject has known hypersensitivity to tacrolimus, macrolide antibiotics, mycophenolate mofetil, or any of the product excipients.
- Subject is unlikely to comply with the visits scheduled in the protocol in the opinion of the investigator or has a history of non-compliance.
- Pregnant women, nursing mothers, lactating women, and women of child-bearing potential who are unwilling to use reliable contraception during the study and for 6 weeks following completion of the study.
- Patients with evidence of active liver disease (liver function tests ≥ 2 times upper limit of normal) or the presence of a chronic active hepatitis B or C.
- Recipient or donor is seropositive for human immunodeficiency virus (HIV).
Key Trial Info
Start Date :
July 31 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2015
Estimated Enrollment :
280 Patients enrolled
Trial Details
Trial ID
NCT02267512
Start Date
July 31 2012
End Date
December 31 2015
Last Update
November 1 2024
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing, China
2
Changchun, China
3
Chengdu, China
4
Guangzhou, China